Commercial information Your Choices Regarding Your Information You may have the following rights with respect to your personal information, subject to applicable exceptions: Right to access. You...

Home Newsroom Custom Content Publications High Cost Therapy Profile High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel Intravenous (IV) Autolus Proposed...

Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...

Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics